Chirag, considering that you do not mind me advising, I can provide couple of pointers. Those shall help you trim down number of companies in your portfolio.

Consider all those stocks listed in your portfolio as a watchlist. Then, assign each of them points/ratings for MOS (margin of safety) at CMP and Growth potential.

Once this is done, you’ll be able to organize your stocks by high scoring to low scoring. Then you can take your top picks and remove the rest without emotion.

Yes raviraj you are right.

I am holding too many stocks but it has very difficult for me to monitor all the stocks and moreover the large caps I know i got it in inheritance, so the cost of purchase is almost nil and all are good managed company and all are multibaggers.

Yes, my portfolio value is same as it was in 2007-08, which could have been increased to many folds by this time.

I am facing lot of dilemma in cutting the list down

Still once I was holding >85 stocks in portfolio and has settled at 45 -50, but ideally I want to settle between 20-25 stocks.

Can someone help to reorganize my portfolio ( balanced and high growth )

Thanks….

Hi Chiragjain,
It seems you have too many stocks in your PF, not sure if you’re able to review the performance of all the Stocks and keep track of the Corporate Actions.
Suggest if you can trim to a manageable limit.
Thanks

This looks like a no brainer stock, with everything going right for the stock and company

1. Q1 result was superb as 70 % inc in profit, all four quarters are expected to be like this good.
2. RBI rate cutting will further increase the profitability with NCD/CP financing increasing qoq
3. NIMs will further improve as year passes by, cost of funds decreasing
4. Stock is still illiquid and under owned/undiscovered to some extent by institutions
5. Any fund getting in will lead to further rerating
6. A growth of 30/35 % in itself is a huge growth with NIL NPA
7. RBI reducing risk wt for housing loans will further help. Avg ticket size of 18 lakh is another positive.

Disc : invested

@pikrohit … In my mental model the EPS of 30 for FY16 is given (though we can’t take anything for granted till it actually gets reported ), what I will be looking on EPS front is that how far on north or south of 40 they will end up, the Q2 results should be able to give a good idea about this.

What is working in favor of both Alembic and Torrent now is that they were slow and probably late to make entry into US and historically their US business has been small and that has set up a small base. e.g. US revenue of torrent were 134 MUSD and Alembic had international generic (inc US) revenue of 80 M USD for FY15. Now revenue from single molecule (Abilify) in FY16 will most likely exceed their entire full year FY15 revenue from US generic and will give a big swing to both topline and even more bigger swing to bottomline as contribution to bottomline will be much higher due to lesser price erosion in Abilify because of limited competition compared to a normal generic. On top of abilify we will have Detrol and probably Nexium for Torrent and Celebrex for Alembic plus a robust base business from India and other molecules from international generics.
At a molecule level abilify is a one off opportunity but at the company level both Alembic and Torrent have good product pipeline which can provide similar upside giving decent overall CAGR even after considering abilify effect.
Another company in similar situation is Cipla where a single molecule (Nexium) in US has provided a huge upswing to both top line and bottomline (despite Cipla having a much bigger size) as is evident from Q1 results.